Arcadia Biosciences (RKDA) Tops Q2 EPS by 78c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts RKDA Hot Sheet
Join SI Premium – FREE
Arcadia Biosciences (NASDAQ: RKDA) reported Q2 EPS of $0.61, $0.78 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $1.39 million versus the consensus estimate of $2.3 million.
For earnings history and earnings-related data on Arcadia Biosciences (RKDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UnitedHealth Group (UNH) Tops Q3 EPS by 57c, Beats on Revenue; Offers FY EPS Guidance
- Cryo-Cell International, Inc. (CCEL) Tops Q3 EPS by 13c
- Spotify (SPOT) Reiterated at Market Outperform by Citizens - '2027 Could Represent Inflection Point'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
